Shoreline Biosciences Wins a Comprehensive Summary Judgement Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
Shoreline Biosciences Appoints Scott Forrest, PH.D., as Chief Business Officer
“We’re thrilled to welcome Scott to Shoreline as Chief Business Officer,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “Scott is a highly accomplished executive
Shoreline Biosciences to Present at Upcoming Investor Conferences
San Diego, Calif., September 8, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires
San Diego, Calif., July 13, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Shoreline Biosciences Appoints Mohammad El-Kalay, Ph.D. as Senior VP and Head of CMC
San Diego, Calif., June 28, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Kite and Shoreline Biosciences Enter Into Strategic Partnership To Develop Novel Allogeneic Cell Therapies
— Partnership Follows Kite’s Investment in Shoreline’s Recent Series A Financing — Santa Monica, Calif., and San Diego, June 17, 2021 – Kite, a Gilead
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
SAN DIEGO, CA, CAMBRIDGE, MA & BEIJING, China – June 9, 2021 — Shoreline Biosciences, Inc., a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted